Khwaja Abdul Hamied and the incredible story of Cipla


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
In the 1920s, an affluent father wanted his son to become a barrister. But the son chose to pursue chemistry instead. Learn the incredible story of Khwaja Hamied, the founder of Cipla.

During the 1920s, an affluent father wanted his son to become a barrister, a profession accepted by privileged Indian families in that era. But the son had no interest in studying law. He mounted on his ship of United Kingdom and waved his father goodbye. Halfway across the ocean he switched his ship and landed in Germany. Germany at that time was booming with chemicals and chemists. The son got his education and returned back in India with a degree in chemistry. 

This was none other than Khwaja Abdul Hamied, the founder of Cipla. Coming from Germany with a Jewish wife and chemistry degree, he opened the Chemical, Industrial and Pharmaceutical Laboratories in 1935. This was the predecessor of Cipla which got renamed in 1984. Khwaja Abdul Hamied was a follower of Mahatma Gandhi and Jawaharlal Nehru. He opened his company with the aim to help the poorest of Indians get access to affordable and quality medicines. 

Even after the partition, when Mohammad Ali Jinnah asked a fellow Muslim, Khwaja Hamied, to join Pakistan, Hamied refused. He was a follower of Gandhi and his sympathies were with India. Even while handing over his company to his son, Khwaja Hamied said, “Unlike other pharmaceutical companies around the world, we are not here to make profits but to bring relief and healthcare to the poor who may otherwise have to die for want of quality drugs.”

Yusuf Hamied was the son of Cipla’s founder who had studied chemistry at Cambridge University. He joined the company as an R&D officer. Under him, the bulk of the company’s drugs received USA’s FDA approval. In the 1990s, Cipla made a major breakthrough, they combined three anti-retroviral drugs into one dose. In 1991, the company made a breakthrough in cancer chemotherapy in partnership with the Indian Institute of Chemical Technology. 

Later in 1995, they made the world’s first oral iron chelator named Deferiprone. They also created the world’s first dry powder inhaler device named Rothaler. In 2001, Cipla came up with HIV medicines at a cost of $350 per year per patient, when the whole world was charging $1200 approximately for the same. 

At end of FY19, Cipla had a turnover of Rs 16,792 crores. They were the market leader with a share of 21.8% in respiratory therapy. Cipla has outranked every company to become the best provider of respiratory therapy. With its forte in respiratory disease solutions, Cipla plans to capitalise on the limited competition in the global respiratory medicines and therapies market. They plan to grow products that can deliver drugs into the body through the respiratory tract.

In short, the 86 year old company still has a long journey ahead.

Tags : #KhwajaHamied #Cipla #YusufHamied #IndianPharmaceuticalCompany #globalleader #pharmacy #smitakumar #medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026